ClinicalTrials.gg
Not yet recruitingNCT06702592VITALSSUpdated Nov 12, 2026

Virtual Testis Cancer Lay Support and Survivorship Aim 2

An interventional study of Virtual support and Patient educational material in Testicular Cancer and Testis Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by UNC Lineberger Comprehensive Cancer Center · Not applicable, Interventional, and Health services research

How we know

Updated Nov 12, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 167 studies in Testicular Neoplasms with a site in United States — 21 open to participants now, 26 under way, 1 of them phase 3. Testicular Neoplasms · United States.

Planned enrollment
4th of 111
360 · median 36
Started
2026
with 5 others
No phase
25 of 167
6 open now
Primary completion
2028-06
later than 16 of 25 live
Registered
155th of 167
by date

Among the 167 studies in Testicular Neoplasms with a site in United States, this one is the 4th largest by planned enrollment of the 111 interventional ones that give a count, is one of 6 that started in 2026, is one of 25 with no phase, reaches primary completion later than 16 of the 25 other live ones, and was the 155th registered.

Testicular Neoplasms

295 studies on the registry are indexed under Testicular Neoplasms; 51 are open to participants now.

Browse Testicular Neoplasms studies →

Open to participants now

21 of the 167 studies in Testicular Neoplasms with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Testicular Neoplasms studies recruiting now, 26 (60%) set no upper age limit and 11 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 95 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Testicular Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study examines how virtual support can enhance well-being and survivorship in men with testicular cancer. Participants in North Carolina will be randomized into two groups: one with access to a virtual support platform and the other with access to patient educational materials only. After six months, the emotional well-being, self-efficacy, financial toxicity, and quality of life of both groups will be compared at 3 months and 6 months after baseline assessments.

03

Conditions studied

  • Testicular Cancer
  • Testis Cancer

Keywords

  • virtual support
  • emotional well-being
  • self-efficacy
  • financial toxicity
  • quality of life
04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men within 5 years of their initial diagnosis of germ cell testicular cancer.
  • The subject is willing and able to comply with study procedures based on the judgment of the investigator.
  • Adults aged 18-95 years old.
  • Electronic was obtained to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Woman gender
  • Non-English speaking
  • Unwilling or unable to complete .
  • On active treatment for another cancer.
  • Actively receiving chemotherapy, radiation, or surgery for testicular cancer.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Virtual support

    Participants will have access to the virtual support platform.

    Behavioral: Virtual support

  • Other
    Patient educational material

    Participants will have access to patient educational material only.

    Behavioral: Patient educational material

Interventions

  • BehavioralVirtual support

    Subjects will use a virtual support platform that was built for their needs.

  • BehavioralPatient educational material

    Participants will have access to patient educational material.

06

What researchers measure

Primary outcomes

  1. Emotional well-being scores comparison

    Emotional well-being will be assessed by patient-reported outcomes questionnaires using a 9-item Positive Affect and Well-Being assessment from the Neuro-QOL Item Bank v1. Emotional well-being scores in virtual support and enhanced usual care will be compared. It is a 5-point Likert scale, higher scores reflect better emotional well-being.

    Time frame: At baseline, 3-months, and 6-months

Secondary outcomes

  1. Negative mental health comparison

    Negative mental health will be assessed by patient-reported outcomes questionnaires using 17 PROMIS items for anxiety, depression, loneliness, and stress. Negative mental health scores in virtual support and enhanced usual care will be compared. Scoring: Each item is rated on a 5-point scale between never (1) to always (5). The responses for each item are summed to get a total raw score. T-Scores: The raw score is then converted to a T-score using a scoring table specific to the PROMIS Anxiety item bank. T-scores standardize the results, making them comparable across different populations and studies. A T-score has a mean of 50 and a standard deviation of 10 in the general population.

    Time frame: At baseline, 3-months, and 6-months

  2. Social well-being, acceptance and inclusion comparison

    Social well-being will be assessed by patient-reported outcomes questionnaires using the 6-item Acceptance/Inclusion subscale of the General Belongingness Scale (GBS). GBS measures an individual's sense of belonging and social connectedness. It consists of 12 items that assess feelings of acceptance and inclusion. Each item is rated on a 7-point Likert scale (1 = Strongly Disagree and 7 = Strongly Agree). Higher scores reflect better inclusion. Scores in virtual support and enhanced usual care will be compared.

    Time frame: At baseline, 3-months, and 6-months

  3. Financial Toxicity comparison

    Financial Toxicity will be assessed by patient-reported outcomes questionnaires using a 12-item Comprehensive Score for Financial Toxicity (COST) instrument. Each item is rated on a 5-point Likert scale 0= = Not at all to 4= Very much. Higher scores indicate higher financial difficulties. Scores in virtual support and enhanced usual care will be compared.

    Time frame: At baseline, 3-months, and 6-months

  4. Self-efficacy comparison

    Self-efficacy will be assessed by patient-reported outcomes questionnaires using 20 PROMIS items for self-efficacy for managing daily activities, emotions, social interactions, and symptoms. Self-efficacy scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point scale ( 1 = Never, 5 = Always). Responses are summed to get a total raw score for each domain. Raw scores are converted to T-scores using a scoring table. T-scores standardize results, with a mean of 50 and a standard deviation of 10 in the general population.

    Time frame: At baseline, 3-months, and 6-months

  5. Sexual Function and Satisfaction comparison

    Sexual Function and Satisfaction will be assessed by patient-reported outcomes questionnaires using a 20-item PROMIS SexFS instrument with domains for interest in sexual activity, global satisfaction with sex life, orgasm, and erectile function. Scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point Likert scale: 1 = Not at all to 5= Very much. Raw scores are converted to T-scores using a scoring table specific to the PROMIS Sexual Function and Satisfaction profile. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population.Higher T-scores indicate better sexual function and satisfaction.

    Time frame: At baseline, 3-months, and 6-months

  6. Functional well-being comparison Functional well-being comparison

    Functional well-being will be assessed by patient-reported outcomes questionnaires using a 7-item subscale of the Functional Assessment of Cancer Therapy (FACT-G) instrument. Each item is rated on a 5-point Likert scale, 0= = Not at all to 4= Very much. Higher scores indicate better well-being. Scores in virtual support and enhanced usual care will be compared.

    Time frame: At baseline, 3-months, and 6-months

  7. General Quality of Life comparison

    General Quality of Life will be assessed by patient-reported outcomes questionnaires using the PROMIS Global Health scale is an 8-item, validated survey that represents five core domains (physical function, pain, fatigue, emotional distress, social health). Two items each for physical and mental health as well as a question on quality of life will be administered. Scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point Likert scale:1 = Poor to 5 = Excellent. Responses are summed to get a total raw score. The raw score is converted to a T-score using a scoring table. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population. Higher T-scores indicate better overall health

    Time frame: At baseline, 3-months, and 6-months

  8. General Self-Efficacy comparison

    General Self-Efficacy will be assessed by patient-reported outcomes questionnaires using the 4-item PROMIS instrument that measures the respondent's belief in managing specific problems or issues. Each item is scored on a 5-point Likert scale, 1 = Never to 5 = Always. The raw score is then converted to a T-score using a scoring table specific to the PROMIS domain being measured. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population. Higher T-scores indicate more of the concept being measured Scores in virtual support and enhanced usual care will be compared.

    Time frame: At baseline, 3-months, and 6-months

  9. Virtual platform usage

    Virtual platform usage will be assessed by time, visits, scrolling, posts, and messages spent on the virtual platform.

    Time frame: At baseline, 3-months, and 6-months

  10. Healthcare and supportive care utilization

    Self-reported use of healthcare and supportive care services will be assessed by a survey. Participants will be asked to quantify healthcare or other supportive care visits over the intervention period.

    Time frame: At baseline, 3-months, and 6-months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2028, 18 months later.

Of 31 interventional studies with no phase under Testicular Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 72. This study's planned 18 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Nov 25, 2024
StartEst.
Dec 2026was Sep 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Dec 2026
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date Sep 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06702592
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Nov 25, 2024
Start date
Dec 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Deborah S Usinger
Contact
dusinger@email.unc.edu
919-962-5431
Taylor J Greene
Contact
taylor_greene@med.unc.edu
919-962-5506
Hung-Jui Tan, MD
principal investigator · UNC Lineberger Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion